Antiretroviral agents.
出版信息
IARC Monogr Eval Carcinog Risks Hum. 2000;76:45-173.
Abstract
摘要
相似文献
1
Antiretroviral agents.
IARC Monogr Eval Carcinog Risks Hum. 2000;76:45-173.
2
What we know about anti-HIV drugs.
Treat Rev. 1995 May(no 18):3-4.
3
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
J Infect Dis. 1996 Jun;173(6):1354-66. doi: 10.1093/infdis/173.6.1354.
4
[Antiretroviral therapy. Current status and perspectives].
Internist (Berl). 1994 Oct;35(10):896-900.
5
[Therapy of HIV infection with nucleoside analogs].
Z Gastroenterol. 1993 Nov;31 Suppl 5:60-6.
6
A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease.
Int J STD AIDS. 1995 Jan-Feb;6(1):19-26. doi: 10.1177/095646249500600105.
7
Studies of zidovudine in combination with didanosine and zalcitabine.
J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S52-6.
8
Intermittent therapy.
J Acquir Immune Defic Syndr (1988). 1994 May;7(5):454-6.
9
Zalcitabine and didanosine.
Lancet. 1993 Jan 2;341(8836):30-2. doi: 10.1016/0140-6736(93)92496-g.
10
[HIV infection--current possibilities in antiviral therapy].
Ther Umsch. 1994 Aug;51(8):545-50.
引用本文的文献
1
Azidothymidine Sensitizes Primary Effusion Lymphoma Cells to Kaposi Sarcoma-Associated Herpesvirus-Specific CD4+ T Cell Control and Inhibits vIRF3 Function.
PLoS Pathog. 2016 Nov 28;12(11):e1006042. doi: 10.1371/journal.ppat.1006042. eCollection 2016 Nov.
2
Long-term exposure to zidovudine delays cell cycle progression, induces apoptosis, and decreases telomerase activity in human hepatocytes.
Toxicol Sci. 2009 Sep;111(1):120-30. doi: 10.1093/toxsci/kfp136. Epub 2009 Jun 18.
3
Interference of cell cycle progression by zidovudine and lamivudine in NIH 3T3 cells.
Mutagenesis. 2009 Mar;24(2):133-41. doi: 10.1093/mutage/gen059. Epub 2008 Oct 20.
Zotero 插件